The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

August 16, 2018 • By Vaneet Kaur Sandhu, MD, & Kathleen Teves, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long duration travel helps us understand potential treatment and prevention of the same in APS patients.

You Might Also Like
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia
  • Antiphospholipid Syndrome
Explore This Issue
August 2018

Clinical Vignette

A 22-year-old woman noted diffuse severe abdominal pain while traveling by plane from California to India. Each episode began with a bloating sensation that progressed to cramping pain with nausea but no emesis, no relation to food intake and eventual resolution of symptoms without intervention. Such symptoms recurred with any long flights she took, typically to and from India.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

One year later, a comprehensive evaluation, including negative infectious workup, yielded the diagnosis of irritable bowel syndrome and cholelithiasis without cholecystitis. After undergoing an elective cholecystectomy, her postoperative course was complicated by renal infarction (see Figure 1A) followed by splenic (see Figure 1B), ovarian and mesenteric infarction within one week. Serologic examination was significant for elevated serum cardiolipin antibody titers, yielding a diagnosis of catastrophic antiphospholipid syndrome.

Figure 1

Figure 1

She was subsequently treated with anticoagulation in addition to plasmapheresis and rituximab. However, the question of prior symptoms then arose: Was her initial abdominal pain actually mesenteric ischemia? Could this have been prevented?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Clinical Problem

Although vast numbers of individuals travel by air yearly, many remain unaware of the risk of deep vein thrombosis (DVT) and venous thromboembolism (VTE) posed by time spent at high altitudes with prolonged immobility, even in healthy individuals. Those with hypercoagulable conditions, such as APS, are at even greater risk. The literature describing the clotting risk with prolonged travel (typically greater than eight hours) is extensive.1 However, limited data describe a specific association between clotting risk and high altitudes in patients with APS. For this reason, we conducted a literature review to evaluate the association of high altitudes and clotting in patients with APS, in addition to management recommendations in such situations.

The Evidence

Individuals ascending to altitudes greater than 2,400–3,000 meters have demonstrated hypobaric hypoxia and its effects on the coagulation system, including decreased tissue oxygenation and sympathetic compensatory changes.2,3 In 2006, Peter Bärtsch, MD, described healthy mountaineers suffering from altitude-induced thrombosis and subsequent death.4 Hypoxemia activates transcription factor early growth response-I (EGR-1), which results in vascular fibrin deposition. This is amplified by a concomitant suppression of fibrinolysis by upreguation of plasminogen activator inhibitor-1.5

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Antiphospholipid Antibody Syndrome (APS), blood clot, Hughes SyndromeIssue: August 2018

You Might Also Like:
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia
  • Antiphospholipid Syndrome
  • Antiphospholipid Antibody Syndrome

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.